Loading
A phase 1/2 trial of Opamtistomig run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma. is a phase 1/2 interventional study registered as NCT07099430 by Nanjing Leads Biolabs Co.,Ltd, with 280 participants planned, started 2025-09-05. Conditions recorded: Advanced Melanoma. Interventions recorded: LBL-024 for Injection and Toripalimab Injection.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs, Melanoma and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Shares Opamtistomig, Nanjing Leads Biolabs and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/